298 related articles for article (PubMed ID: 10910140)
21. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
[TBL] [Abstract][Full Text] [Related]
22. Targeting human glioma cells using HSV-1 amplicon peptide display vector.
Ho IA; Miao L; Sia KC; Wang GY; Hui KM; Lam PY
Gene Ther; 2010 Feb; 17(2):250-60. PubMed ID: 19812609
[TBL] [Abstract][Full Text] [Related]
23. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
24. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
25. An HSV amplicon-based helper system for helper-dependent adenoviral vectors.
Kubo S; Saeki Y; Chiocca EA; Mitani K
Biochem Biophys Res Commun; 2003 Aug; 307(4):826-30. PubMed ID: 12878185
[TBL] [Abstract][Full Text] [Related]
26. An enhanced packaging system for helper-dependent herpes simplex virus vectors.
Stavropoulos TA; Strathdee CA
J Virol; 1998 Sep; 72(9):7137-43. PubMed ID: 9696807
[TBL] [Abstract][Full Text] [Related]
27. Construction and packaging of herpes simplex virus/adeno-associated virus (HSV/AAV) Hybrid amplicon vectors.
Saydam O; Glauser DL; Fraefel C
Cold Spring Harb Protoc; 2012 Mar; 2012(3):352-6. PubMed ID: 22383640
[TBL] [Abstract][Full Text] [Related]
28. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
Miyatake S; Martuza RL; Rabkin SD
Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
[TBL] [Abstract][Full Text] [Related]
29. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer.
Todryk S; McLean C; Ali S; Entwistle C; Boursnell M; Rees R; Vile R
Hum Gene Ther; 1999 Nov; 10(17):2757-68. PubMed ID: 10584922
[TBL] [Abstract][Full Text] [Related]
30. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.
Wallenfriedman MA; Conrad JA; DelaBarre L; Graupman PC; Lee G; Garwood M; Gregerson DS; Jean WC; Hall WA; Low WC
J Neurosurg; 1999 Jun; 90(6):1064-71. PubMed ID: 10350253
[TBL] [Abstract][Full Text] [Related]
31. Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector.
Ho IA; Hui KM; Lam PY
Hum Gene Ther; 2004 May; 15(5):495-508. PubMed ID: 15144579
[TBL] [Abstract][Full Text] [Related]
32. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
[TBL] [Abstract][Full Text] [Related]
33. Generation of high-titer defective HSV-1 vectors.
Lim F; Neve RL
Curr Protoc Neurosci; 2001 May; Chapter 4():Unit 4.13. PubMed ID: 18428477
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells.
Pan D; Wei X; Liu M; Feng S; Tian X; Feng X; Zhang X
Neurol Res; 2010 Jun; 32(5):502-9. PubMed ID: 19589203
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.
Willis RA; Bowers WJ; Turner MJ; Fisher TL; Abdul-Alim CS; Howard DF; Federoff HJ; Lord EM; Frelinger JG
Hum Gene Ther; 2001 Oct; 12(15):1867-79. PubMed ID: 11589829
[TBL] [Abstract][Full Text] [Related]
36. An efficient selection system for packaging herpes simplex virus amplicons.
Zhang X; O'Shea H; Entwisle C; Boursnell M; Efstathiou S; Inglis S
J Gen Virol; 1998 Jan; 79 ( Pt 1)():125-31. PubMed ID: 9460933
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
38. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus.
Logvinoff C; Epstein AL
Hum Gene Ther; 2001 Jan; 12(2):161-7. PubMed ID: 11177553
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
40. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
Janousková O; Síma P; Kunke D
Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
